Nasdaq:US$12.40 (-0.88) | HKEX:HK$21.60 (+1.00) | AIM:£2.16 (+0.05)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.